Altimmune, Inc.
NASDAQ:ALT
3.71 (USD) • At close September 8, 2025
 Overzicht | Financiële gegevens
 | Bedrijfsnaam | Altimmune, Inc. | 
| Symbool | ALT | 
| Munteenheid | USD | 
| Prijs | 3.71 | 
| Beurswaarde    |  327,434,583 | 
| Dividendpercentage    |  0% | 
| 52-weken bereik | 2.9 - 11.16 | 
| Industrie | Biotechnology | 
| Sector | Healthcare | 
| CEO | Dr. Vipin K. Garg Ph.D. | 
| Website | https://altimmune.com | 
An error occurred while fetching data.
Over Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is 
 Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)








